ストックスクリーナーアプリを入手
3.20
3.23%
0.10
アフターアワーズ：
3.13
-0.07
-2.19%
前日終値:
$3.10
開ける：
$3.2
24時間の取引高:
34,087
Relative Volume:
28.44
時価総額：
$32.45M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+0.00%
1か月 パフォーマンス:
+0.00%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$3.10
$3.27
1週間の範囲:
$3.10
$3.32
52週間の値動き範囲:
$3.10
$3.32
Grace Therapeutics Inc Stock (GRCE) Company Profile
Grace Therapeutics Inc (GRCE) 最新ニュース
Corcept Trumps Q3 Earnings & Sales Estimates, Ups '24 Revenue View - MSN
Biopharma Co. Can't Knock Ex-CFO's Bias Suit Out Of Court - Law360
Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing’s Syndrome and Provides Corporate Update - StockTitan
GRCE (Grace Therapeutics) Cash Flow from Financing : $7.36 Mil (TTM As of Jun. 2024) - GuruFocus.com
Acasti Pharma Inc. Announces Poster Detailing Its GTX-104 STRIVE-ON Trial - Marketscreener.com
Grace Therapeutics to Host Virtual KOL Event on GTx-104 in aneurysmal Subarachnoid Hemorrhage on November 20, 2024 - The Manila Times
OTC Markets Hosts Virtual Investor Presentation with Prashant Kohli, CEO of Grace Therapeutics (Acasti Pharma), with John Vandermosten, Senior Analyst at Zacks SCR - MSN
Acasti Pharma Inc. Announces Resignation of Jean-Marie Canan from Board of Directors and Member of Audit Committee and Governance and Human Resources Committee - Marketscreener.com
Grace Therapeutics announces name change and new ticker - Investing.com India
KB Financial Group (NYSE:KB) Sets New 1-Year High – Should You Buy? - Defense World
Acasti Pharma transitions to Grace Therapeutics, trading as GRCE - Investing.com India
ACSTAcasti Pharma, Inc. Latest Stock News & Market Updates - StockTitan
Hurco Poised to Pioneer the Future of Manufacturing - The Manila Times
Acasti Announces Corporate Name Change to Grace Therapeutics, Inc. - GlobeNewswire
Student loan grace period expires: What borrowers need to know - Yahoo Finance
Acasti Pharma Inc. Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104 - Marketscreener.com
Seeking Online Therapy as a Christian? Look No Further Than These 6 Companies - Verywell Mind
H. Jack West, MD - Oncology News Central
Relacorilant shows significant benefits in Cushing’s patients in trial - Cushing's Disease News
Andelyn Biosciences Partners With Grace Science To Advance GS-100 - Contract Pharma
This biotech incubator has built 100+ companies by asking, What if . . . ? - Fast Company
Acasti: Fiscal Q3 Earnings Snapshot - Marketscreener.com
AstraZeneca pays $1B to take the wheel of Gracell’s CAR-T ‘fast car’ - Fierce Biotech
AstraZeneca to buy China's Gracell Biotechnologies in $1.2 billion deal - Reuters.com
Jaguar Health Receives Additional 180-day Grace Period to Regain Compliance with Nasdaq's Bid Price Rule - Yahoo Finance
Halle Berry’s number one tip for going number two - Fast Company
Chinese CAR T-maker Gracell raises $150M in private financing - BioWorld Online
Trial data for Cushing's treatments relacorilant, Korlym due next year - Cushing's Disease News
Biogen to Acquire Reata Pharmaceuticals - Vinson & Elkins LLP
Pear Therapeutics was sold for parts to four companies for about $6M last week. - Axios
NJ Bioscience Center-Incubator - NJEDA (.gov)
Corcept planning to seek relacorilant approval for Cushing’s in 2024 - Cushing's Disease News
Acasti Pharma Inc. to Proceed with Phase 3 Clinical Safety Study for GTX-104 - Marketscreener.com
GRACE Phase 3 trial of relacorilant nears complete enrollment - Cushing's Disease News
Early‐onset reduced bone mineral density in patients with pyruvate kinase deficiency - Wiley Online Library
Acasti Pharma to Report Second Quarter 2023 Financial Results on Monday, November 14, 2022 - Quantisnow
Nonprofit FAST Has Cure for Angelman Syndrome in Its Sights |... - Angelman Syndrome News
Tiny arms, big relief: Finally a COVID-19 vaccine for Mattie Grace - Walgreens Boots Alliance
Pfizer and Moderna rapidly falling out of favor as Americans' favorite brands: report - FiercePharma
Corcept Will Seek FDA Approval of Relacorilant in 2023 - Cushing's Disease News
Alira Health Expands its Digital Health Portfolio with the Acquisition of Self Care Catalysts - Business Wire
Grace Simoni Obituary (19502015)Lubbock, TXLubbock Avalanche-Journal - Legacy.com
The Champion for Rare Disease Cures - proto.life
Parexel Appoints Chief Patient Officer - Contract Pharma
How to convert your intellectual property IP - EisnerAmper
Biotech Penny Stocks Pushing Up During The Crypto Crash, One Up 25% - Penny Stocks
Acasti Pharma to Acquire Indian Origin Emerging Biopharmaceutical Grace Therapeutics - News18
US-based Acasti Pharma to buy Indian origin pharma firm Grace - The Economic Times
Nature’s Grace and JC Pharma Inc Release CannatolRx Nasal Rescue Spray - mg Magazine
Up Cannabis Reveals Strains Named After Tragically Hip Songs - Exclaim!
Grace Therapeutics Inc (GRCE) 財務データ
Grace Therapeutics Inc (GRCE) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
1.11%
0.26%
大文字化:
|
ボリューム (24 時間):